Close Menu

Regeneron Inks Research Pact with UT-Southwestern Medical for Human mAbs

Regeneron Pharmaceuticals said this week that it will provide researchers at the University of Texas Southwestern Medical Center with access to Regeneron’s VelocImmune technology to discover fully human monoclonal antibodies.

Under the agreement, scientists at UT Southwestern will use VelocImmune mice to generate antibodies against their research targets and will conduct research to discover potential human therapeutics based on the antibodies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

Time magazine looks into how liquid biopsies are changing cancer care.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.